☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Securities registered pursuant to Section 12(b) of the Securities Exchange Act: None

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Indicate by check mark whether the registrant has submitted electronically ~~and posted on its corporate Web site, if any,~~ every Interactive Data File required to be submitted ~~and posted~~ pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit ~~and post~~ such files). Yes ☒ No ☐☐

Indicate by check mark whether the registrant is a large-accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large-accelerated filer,” “accelerated filer,” “non-accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

As of ~~August 20, 2021,~~May 19, 2022, there were ~~65,759,771~~140,627,538 shares of common stock, $0.0001 par value issued and outstanding.

	June 30, 2021			December 31, 2020				March 31, 2022			December 31, 2021
	(Unaudited)			(Audited)			(Unaudited)			(Audited)

ASSETS
Current assets:
Cash	$	8,538		$	13,420		$	59,982		$	85,936
Accounts receivable, net of allowance for doubtful accounts of $0		9,417			942			945			944
Prepaid expenses and other current assets		20,725			31,825			3,500			7,975
Total current assets		38,680			46,187			64,427			94,855

Property, Plant and Equipment, net		-			1,580
Patents, net		2,235,812			2,559,268			1,750,628			1,912,356
Total assets	$	2,274,492		$	2,607,035		$	1,815,055		$	2,007,211

LIABILITIES AND SHAREHOLDERS’ DEFICIT
Current liabilities
Accounts payable	$	711,235		$	700,932		$	704,018		$	658,463
Accrued interest		2,164,506			1,904,136			2,759,929			2,528,459
Deferred compensation		3,739,806			3,384,117			4,042,411			3,891,361
Notes payable, net of discounts of $70,236 and $201,157 as of June 30, 2021, and December 31, 2020		6,538,340			6,491,039
Notes payable, net of discounts of $60,877 and $75,800 as of March 31, 2022, and December 31, 2021								7,169,953			7,055,030
Notes payable – former related party		121,000			143,000			123,100			126,100
Derivative liability		5,903,803			4,202,597			4,972,655			3,442,297

Total current liabilities		19,178,690			16,825,821			19,772,066			17,701,710

Acquisition payable		79,825			155,000			79,825			79,825
Total liabilities		19,258,515			16,980,821			19,851,891			17,781,535
COMMITMENTS AND CONTINGENCIES, note 10		-			-
COMMITMENTS AND CONTINGENCIES, note 9								-			-

Shareholders’ deficit
Super AA super voting preferred stock, $0.001 par value; 1,000,000 authorized and 25,000 issued and outstanding at June 30, 2021, and December 31, 2020		25			25
Preferred stock value		-			-
Series B convertible preferred stock, $0.0001 par value; 50,000 shares authorized, 600 shares issued and outstanding at June 30, 2021, and December 31, 2020		1			1
Preferred stock value		-			-
Super AA super voting preferred stock, $0.001 par value; 1,000,000 authorized and 25,000 issued and outstanding at March 31, 2022, and December 31, 2021								25			25
Series B convertible preferred stock, $0.0001 par value; 50,000 shares authorized, 600 shares issued and outstanding at March 31, 2022, and December 31, 2021								1			1

Series C convertible preferred stock, $0.0001 par value; 8,000 shares authorized, 738 and 763 shares issued and outstanding at June 30, 2021, and December 31, 2020		-			-
Preferred stock value		-			-
Series C convertible preferred stock, $0.0001 par value; 8,000 shares authorized, 738 shares issued and outstanding at March 31, 2022, and December 31, 2021								-			-

Series D convertible preferred stock, $0.0001 par value; 20,000 shares authorized, 305 issued and outstanding at June 30, 2021, and December 31, 2020		-			-
Preferred stock value		-			-
Series D convertible preferred stock, $0.0001 par value; 20,000 shares authorized, 305 issued and outstanding at March 31, 2022, and December 31, 2021								-			-
Preferred value								-

Common stock, $0.0001 par value; 2,500,000,000 shares authorized; 60,659,771 and 24,536,689 shares issued and outstanding as of June 30, 2021, and December 31, 2020		6,067			2,453
Common stock, $0.0001 par value; 2,500,000,000 shares authorized; 81,327,538 and 74,498,761 shares issued and outstanding as of March 31, 2022, and December 31, 2021								8,132			7,449
Additional paid-in capital		40,327,526			38,963,827			40,813,201			40,663,187
Stock subscriptions		(1,570	)		(1,570	)		(1,570	)		(1,570	)
Accumulated deficit		(57,316,072	)		(53,338,522	)		(58,856,625	)		(56,443,416	)
Total shareholders’ deficit		(16,984,023	)		(14,373,786	)		(18,036,836	)		(15,774,324	)
Total liabilities and shareholders’ deficit	$	2,274,492		$	2,607,035		$	1,815,055		$	2,007,211

See accompanying summary of accounting policies and notes to unaudited condensed consolidated financial statements.

	2021			2020			2021			2020				2022			2021
	Three Months Ended						Six Months Ended						Three Months Ended
	June 30,						June 30,						March 31,
	2021			2020			2021			2020			2022			2021

Revenue	$	30,284		$	44,631		$	64,999		$	114,316		$	2,282		$	34,715
Cost of revenue		500			11,300			3,021			17,560			714			2,521
Gross profit		29,784			33,331			61,978			96,756			1,568			32,194

Operating expenses		599,837			635,157			1,222,475			1,378,194			487,330			622,638
Loss from operations		(570,053	)		(601,826	)		(1,160,497	)		(1,281,438	)		(485,762	)		(590,444	)

Other income (expense)
Other expense
Change in fair value of derivative liability		(720,439	)		(861,147	)		(2,420,449	)		5,600,255			(1,530,358	)		(1,700,010	)
Gain (loss) on settlement of debt		114,021			92,492			70,996			(516,783	)
Loss on settlement of debt														(60,947	)		(43,025	)
Interest expense, net		(120,198	)		(264,170	)		(467,600	)		(1,098,267	)		(336,142	)		(347,402	)
Other income (expense)		(726,616	)		(1,032,825	)		(2,817,053	)		3,985,205
Other expense														(1,927,447	)		(2,090,437	)

Income (Loss) before income taxes		(1,296,669	)		(1,634,651	)		(3,977,550	)		2,703,767
Loss before income taxes														(2,413,209	)		(2,680,881	)

Provision for income taxes		-			-			-			-			-			-

Net Income (loss) income	$	(1,296,669	)	$	(1,634,651	)	$	(3,977,550	)	$	2,703,767
Net loss income													$	(2,413,209	)	$	(2,680,881	)

Basic Income (Loss) per share	$	(0.02	)	$	(0.17	)	$	(0.08	)	$	0.42
Diluted Income (Loss) per share	$	(0.02	)	$	(0.17	)	$	(0.08	)	$	(0.15	)
Basic Loss per share													$	(0.03	)	$	(0.06	)
Diluted Loss per share													$	(0.03	)	$	(0.06	)
Weighted average common share outstanding:
Basic		58,487,227			9,833,073			50,084,150			6,368,543
Diluted		58,487,227			9,833,073			50,084,150			15,065,162
Basic and Diluted														79,005,583			41,570,483

See accompanying summary of accounting policies and notes to unaudited condensed consolidated financial statements.

	2021			2020				2022			2021
	Six Months ended June 30,						Three Months ended March 31,
	2021			2020			2022			2021
Operating activities:
Net (Loss) Income	$	(3,977,550	)	$	2,703,767
Adjustments to reconcile net (loss) income to cash used in operating activities:
Net Loss							$	(2,413,209	)	$	(2,680,881	)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation and amortization expense		325,036			325,053			161,728			163,308
Stock compensation expense		40,961			55,540			-			20,471
Fair value of commitment shares issued with debt		33,470			-			-			27,170
Fair value of equity issued for services		-			13,067
Loss (gain) on extinguishment of debt		(70,996	)		516,783			60,947			43,025
Amortization of note discount and original issue discount		72,751			36,843			30,674			42,000
Amortization of discount on Series C Preferred stock liability		-			248
Non-cash interest expense		-			550,994
Change in fair value of derivative liability		2,420,449			(5,600,255	)		1,530,358			1,700,010
Changes in assets and liabilities:
Accounts receivable		(8,475	)		21,801			-			(6,535	)
Prepaid expenses and other current assets		11,100			17,560			4,475			1,100
Account payable		10,304			9,936			45,554			20,908
Accrued interest		361,379			510,184			305,469			278,232
Deferred compensation		355,689			385,486			151,050			101,244
Net cash used in operating activities		(425,882	)		(452,061	)		(122,954	)		(289,948	)

Financing activities:
Proceeds from the issuance of notes payable		325,000			401,424			100,000			250,000
Repayments on former related-party of notes payable		(22,000	)		(13,000	)
Repayments to former related-party of notes payable								(3,000	)		(5,500	)
Repayments of convertible debt in cash		(8,000	)		-			-			(8,000	)
Proceeds from issuance of common stock and units		126,000			-			-			126,000
Proceeds from issuance of preferred stock		-			50,000

Net cash provided by financing activities		421,000			438,424			97,000			362,500

Net decrease in cash		(4,882	)		(13,637	)
Net (decrease) increase in cash								(25,954	)		72,552
Cash, beginning of year		13,420			18,893			85,936			13,420
Cash, end of period	$	8,538		$	5,256		$	59,982		$	85,972

Supplemental disclosure of cash flow information:
Cash paid for interest	$	-		$	-		$	-		$	-
Cash paid for income taxes	$	-		$	-		$	-		$	-

Non-Cash Investing and Financing Activities:
Conversion of notes payable and accrued interest to common stock	$	501,629		$	1,311,240		$	74,000		$	310,046
Conversion of Preferred C Stock to common stock	$	33,333		$	1,387,601
Issuance of common stock to Preferred C Stock inducement	$	-		$	8,152
Exchange note and accrued interest to new convertible note	$	-		$	316,494

See accompanying summary of accounting policies and notes to unaudited condensed consolidated financial statements.

Endonovo Therapeutics, Inc. (Endonovo or the “Company”) is an innovative biotechnology company that has developed a bio-electronic approach to regenerative medicine. Endonovo is a growth stage company whose stock is publicly traded (OTCQB: ENDV).

The Company develops, manufactures, and distributes evolutionary medical devices focused on the rapid healing of wounds and reduction of pain, edema, and inflammation in the human body. The Company’s non-invasive bioelectric medical devices are designed to target inflammation, cardiovascular diseases, chronic kidney disease, and central nervous system disorders (“CNS” disorders).

The Company’s non-invasive Electroceutical® therapeutics device, SofPulse®, using pulsed short-wave radiofrequency at 27.12 MHz has been FDA-Cleared and CE Marked for the palliative treatment of soft tissue injuries and post-operative plain and edema, and has CMS National Coverage for the treatment of chronic wounds. The Company’s current portfolio of pre-clinical stage Electroceutical® therapeutics devices address chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular and peripheral artery disease (PAD) and ischemic stroke.

Endonovo’s core mission is to transform the field of medicine by developing safe, wearable, non-invasive bioelectric medical devices that deliver the Company’s Electroceutical^® Therapy. Endonovo’s bioelectric Electroceutical^® devices harnesses bioelectricity to restore key electrochemical processes that initiate anti-inflammatory processes and growth factors in the body necessary for healing to rapidly occur.

The accompanying unaudited interim condensed consolidated financial statements have been presented in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and the instructions to Article 8 of Regulation S-X. Accordingly, the financial statements do not include all of the information and notes required by GAAP for complete financial statements. The condensed consolidated financial statements as of ~~June 30,~~March 31, 2022, and 2021, ~~and 2020,~~ are unaudited; however, in the opinion of management such interim condensed consolidated financial statements reflect all adjustments, consisting solely of normal recurring adjustments, necessary for a fair presentation of the results for the periods presented. The accompanying financial information should be read in conjunction with the financial statements and the notes thereto in the Company’s most recent Annual Report on Form 10-K, as filed with the Securities and Exchange Commission (the “SEC”) on April ~~13, 2021.~~14, 2022. The results of operations for the period presented are not necessarily indicative of the results that might be expected for future interim periods or for the full year.

The Company’s unaudited condensed consolidated financial statements are prepared using GAAP applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has not yet established an ongoing source of revenues sufficient to cover its operating costs and allow it to continue as a going concern. The ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until it becomes profitable.

As of ~~June 30, 2021,~~March 31, 2022, the Company had cash of approximately $~~8,500~~60,000 and a working capital deficiency of approximately $~~19.1~~19.7 million. During the ~~six~~three months ended ~~June 30, 2021,~~March 31, 2022, the Company used approximately $~~0.4~~0.1 million of cash in its operation. The Company has incurred recurring losses resulting in an accumulated deficit of approximately $~~57.3~~58.9 million as of ~~June 30, 2021.~~March 31, 2022. These conditions raise substantial doubt as to its ability to continue as going concern within one year from issuance date of these financial statements.

During the ~~six~~three months ended ~~June 30, 2021,~~March 31, 2022, the Company has raised approximately $~~0.5~~0.1 million in debt ~~and equity financing.~~financing through the issuance of the promissory note. The Company is raising additional capital through debt and equity securities to continue the funding of its operations. However, there is no assurance that the Company can raise enough funds or generate sufficient revenues to pay its obligations as they become due, which raises substantial doubt about our ability to continue as a going concern.

No adjustments have been made to the carrying value of assets or liabilities as a result of this uncertainty. To reduce the risk of not being able to continue as a going concern, management is commercializing its FDA cleared and CE marked products and has commenced implementing its business plan to materialize revenues from potential, future, license agreements, has raised capital through the sale of its common stock, and the issuance of convertible promissory ~~notes.~~

In March 2020, the World Health Organization declared coronavirus COVID-19 a global pandemic. This contagious disease outbreak, which has continued to spread, and any related adverse public health developments, has adversely affected workforces, economies, and financial markets globally, potentially leading to an economic downturn. It is not possible for the Company to predict the duration or magnitude of the adverse results of the outbreak and its effects on the Company’s business or ability to raise funds.

~~Notes to Condensed Consolidated Financial Statements (continued)~~notes with embedded conversion features.

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Critical estimates include the value of shares issued for services, in connection with notes payable agreements, in connection with note extension agreements, and as repayment for outstanding debt, the useful lives of property and equipment, the valuation of the derivative liability, the valuation of warrants and stock options, and the valuation of deferred income tax assets. Management uses its historical records and knowledge of its business in making these estimates. Actual results could differ from these estimates.

The Company utilizes Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 260, “Earnings per Share.” Basic earnings (loss) per share is computed based on the earnings (loss) attributable to common shareholders divided by the weighted average number of shares outstanding for the period excluding any dilutive effects of options, warrants, unvested share awards and convertible securities. Diluted earnings (loss) per common share is calculated similar to basic earnings (loss) per share except that the denominator is increased to include additional common share equivalents available upon exercise of stock option, warrants, common shares issuable under convertible debt and restricted stock using the treasury stock method. Dilutive common share equivalents include the dilutive effect of in-the-money share equivalents, which are calculated based on the average share price for each period using the treasury stock method, excluding any common share equivalents if their effect would be anti-dilutive. In periods in which a net loss has been incurred, all potentially dilutive common shares are considered anti-dilutive and thus are excluded from the calculation. Securities that are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been antidilutive for the ~~six~~three months ended ~~June 30, 2021,~~March 31, 2022, include stock options, warrants, and notes payable.

The Company has ~~3,013,730~~513,730 options and ~~28,309~~9,770 warrants to purchase common stock outstanding at ~~June 30, 2021.~~March 31, 2022. The Company has ~~96,533~~3,013,730 options and ~~71,078~~30,525 warrants to purchase common stock outstanding at ~~June 30, 2020.~~March 31, 2021.

~~The components of basic and diluted earnings per share for the six months ended June 30, 2021, and 2020 were as follows:~~

The Company uses the specific identification method for recording the provision for doubtful accounts, which was $0 ~~at June 30, 2021,~~as of March 31, 2022, and December 31, ~~2020.~~2021. Account receivables are written off when all collection attempts have failed.

~~Costs relating to the development of new products are expensed as research and development as incurred in accordance with FASB Accounting Standards Codification (“ASC”) 730-10,~~ ~~Research and Development~~~~. Research and development costs amounted to $~~0 ~~and $3,283~~ ~~for the six months ended June 30, 2021, and 2020, respectively, and are included in operating expenses in the condensed consolidated statements of operations.~~

~~In May 2021, the FASB issued~~ ~~ASU 2021-04~~, Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40), which addresses issuer’s accounting for certain modifications or exchanges of freestanding equity-classified written call options. This amendment is effective for all entities, for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted. The Company is evaluating the effects, if any, of the adoption of ~~ASU 2021-04~~ ~~guidance on the Company’s financial position, results of operations and cash flows.~~

In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework- Changes to the Disclosure Requirements for Fair Value Measurement. The amendments in this Update modify the disclosure requirements on fair value measurements in Topic 820, Fair Value Measurement, based on the concepts in the Concepts Statement, including the consideration of costs and benefits. Effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. Early adoption is permitted upon issuance of this Update. Any entity is permitted to early adopt any removed or modified disclosures upon issuance of this Update and delay adoption of the additional disclosures until their effective date. The Company adopted ASU 2018-13 as of January 1, 2020, and ASU 2018-13 has not had a material impact on the condensed consolidated financial position or results of operations and liquidity.

In August 2020, the FASB issued ASU No. 2020-06 (“ASU 2020-06”) “Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity.” ASU 2020-06 simplifies the accounting for convertible instruments by reducing the number of accounting models for convertible debt instruments and convertible preferred stock. Limiting the accounting models results in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. In addition, ASU 2020-06 amends the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. The Amendments also affects the diluted EPS calculation for instruments that may be settled in cash or shares and for convertible instruments. The amendments are effective for public entities excluding smaller reporting companies for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods. The Company adopted the new standard update on January 1, 2021, which did not result in a material impact on the Company’s condensed consolidated results of operations, financial position, and cash flows.

The Company has evaluated all the recent accounting pronouncements and determined that there are no other accounting pronouncements that will have a material effect on the Company’s financial statements.

The Company adopted ASC 606, Revenue from Contracts with Customers effective January 1, 2019, using the modified retrospective method applied to those contracts which were not substantially completed as of January 1, 2019. These standards provide guidance on recognizing revenue, including a five-step model to determine when revenue recognition is appropriate. The standard requires that an entity recognize revenue to depict the transfer of control of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.

The Company routinely plan on entering into contracts with customers that include general commercial terms and conditions, notification requirements for price increases, shipping terms and in most cases prices for the products and services that we offer. The Company’s performance obligations are established when a customer submits a purchase order notification (in writing, electronically or verbally) for goods and services, and we accept the order. The Company identified performance obligations as the delivery of the requested product or service in appropriate quantities and to the location specified in the customer’s contract and/or purchase order. The Company generally recognize revenue upon the satisfaction of these criteria when control of the product or service has been transferred to the customer at which time, the Company has an unconditional right to receive payment. The Company’s sales and sale prices are final, and our prices are not affected by contingent events that could impact the transaction price.

Revenues for our SofPulse® product is typically recognized at the time the product is shipped, at which time the title passes to the customer, and there are no further performance obligations.

In connection with offering products and services provided to the end user by third-party vendors, the Company reviews the relationship between us, the vendor, and the end user to assess whether revenue should be reported on a gross or net basis. In asserting whether revenue should be reported on a gross or net basis, the Company considers whether the Company acts as a principal in the transaction and control the goods and services used to fulfill the performance obligation(s) associated with the transaction.

~~As of June 30,~~For the three months ended March 31, 2022, and 2021, ~~and 2020,~~ the sources of revenue were as follows:

Our general product warranties do not extend beyond an assurance that the product delivered will be consistent with stated specifications and do not include separate performance obligations.

There are no significant judgments associated with the satisfaction of our performance obligations. We generally satisfy performance obligations upon shipment of the product to the customer. This is consistent with the time in which the customer obtains control of the products. Performance obligations are also generally settled quickly after the purchase order acceptance, therefore the value of unsatisfied performance obligations at the end of any reporting period is generally immaterial.

We consider variable consideration in establishing the transaction price. Forms of variable consideration applicable to our arrangements include sales returns, rebates, volume-based bonuses, and prompt pay discounts. We use historical information along with an analysis of the expected value to properly calculate and to consider the need to constrain estimates of variable consideration. Such amounts are included as a reduction to revenue from the sale of products in the periods in which the related revenue is recognized and adjusted in future periods as necessary.

Our payment terms for sales direct to distributors are substantially less than the one-year collection period that falls within the practical expedient in determination of whether a significant financing component exists.

~~The following is a summary of equipment, at cost, less accumulated depreciation at June 30, 2021, and December 31, 2020:~~

~~Depreciation expense for the six months ended June 30, 2021, and 2020 was $1,580~~ ~~and $2,529, respectively.~~

In December 2017, we acquired from Rio Grande Neurosciences, Inc. (RGN) a patent portfolio for $4,500,000. The earliest patents expire in 2024. The following is a summary of patents less accumulated amortization at ~~June 30, 2021,~~March 31, 2022, and December 31, ~~2020:~~2021:

	June 30, 2021		December 31, 2020		March 31, 2022		December 31, 2021

Patents	$	4,500,000	$	4,500,000	$	4,500,000	$	4,500,000

Less accumulated amortization		2,264,188		1,940,732		2,749,372		2,587,644

Patents, net	$	2,235,812	$	2,559,268	$	1,750,628	$	1,912,356

Amortization expense associated with patents was $~~323,456~~161,728 for the ~~six~~three months ended ~~June 30, 2021,~~March 31, 2022, and ~~2020.~~ 2021.

The estimated future amortization expense related to patents as of ~~June 30, 2021,~~March 31, 2022, is as follows:

During the ~~six~~three months ended ~~June 30, 2021,~~March 31, 2022, the Company issued ~~four (4)~~one (1) fixed rate promissory notes totaling $~~325,000~~ 100,000for funding of $~~325,000~~100,000 with original terms of nine months and interest rates of 15%. The holder of the promissory note can convert the outstanding unpaid principal and accrued interest at a fixed conversion rate, subject to standard anti-dilution features, six-month after issuance date.

As of March 31, 2022, the fixed-rate notes had an outstanding balance of $1,835,000, of which $1,035,000 are past maturity. As of March 31, 2022, the Company has 14 fixed rate promissory notes with unrelated parties for total amount of $1,835,000

During the three months ended March 31, 2022, the Company converted $74,000 in accrued but unpaid interest into 3,700,000 shares of common stock.

As of March 31, 2022, the Company has a total of fourteen (14) fixed-rate notes, of which ten (10) for total principal amount of $1,100,000 includes a make good shares provision. Such provision will require the Company to issue additional shares to ensure that the investor can realize a profit of 15% reselling the conversion shares. The value of the make good provision is not material as of March 31, 2022.

Certain fixed-rate notes include a prepayment provision, which entitles the holder to a 15% cash premium. The Company concluded that such feature amount was not deemed material at year end.

The gross amount of all convertible notes with variable conversion rates outstanding as of March 31, 2022, is $4,770,926, of which $4,770,926 are past maturity. There has been no conversion of notes into the Company’s common stock during the three months ended March 31, 2022.

During the three months ended March 31, 2021, the Company issued two (2) fixed rate promissory notes totaling $250,000 for funding of $250,000with original terms of twelve months and interest rates of 1515%%. The holders of the promissory notes can convert the outstanding unpaid principal and accrued interest at a fixed conversion rate, subject to standard anti-dilution ~~features~~features..

During the ~~six~~three months ended ~~June 30,~~March 31, 2021, the Company amended the terms of two of its promissory notes to accelerate the conversion feature and amend the conversion price of the instruments. The Company recorded the modification in accordance with ASC 470-50 Debt-Modifications and Extinguishments and recorded $58,407 as loss from debt extinguishment in the condensed consolidated statements of operations.

During the ~~six~~three months ended ~~June 30, 2021, the Company settled one of its promissory note by issuing~~ ~~1,515,152~~ ~~restricted shares of the Company’s common stock with a fifteen percent (~~15~~%) make-whole provision. The Company recorded a gain on debt extinguishment of approximately $128,000~~.

~~During the six months ended June 30,~~March 31, 2021, the Company paid $8,000 in cash for one of its fixed rate promissory notes.

During the ~~six~~three months ended ~~June 30,~~March 31, 2021, the Company converted $~~282,850~~234,700 in principal and $~~91,485~~75,346 in accrued but unpaid interest into ~~21,490,651~~17,686,548 shares of common stock.

The gross amount of all convertible notes with variable conversion rates outstanding at ~~June 30,~~March 31, 2021 is $~~4,770,926~~4,936,846, of which $~~2,660,476~~2,778,246 are past ~~maturity.~~maturity

~~Notes payable to a former related party in the aggregate amount of $121,000~~ ~~were outstanding at June 30, 2021, which are past maturity date. The notes bear interest between~~ 10~~% and~~ 12~~% per annum. During the six months ended June 30, 2021, the Company paid $22,000~~ ~~principal to this former related party.~~

~~As of June 30, 2021, fixed rate notes payable outstanding totaled $1,212,747, of which $160,747~~ ~~is past maturity.~~

Notes payable to a former related party in the aggregate amount of $123,100 were outstanding at March 31, 2022, which are past maturity date. The notes bear interest between 10% and 12% per annum. During the three months ended March 31, 2022, the Company paid $3,000 in principal to this former related party. Refer to Note 7- Related Party Transactions.

As of March 31, 2022, and December 31, 2021, the notes payable activity was as follows:

The Company has authorized 5,000,000 shares of preferred stock which have been designated as follows:

	Number of Shares		Number of Shares Outstanding		Par		Liquidation
	Authorized		at June 30, 2021		Value		Value		Number of Shares Authorized		Number of Shares Outstanding at March 31, 2022		Par Value		Liquidation Value
Series AA		1,000,000		25,000	$	0.0010	$	-		1,000,000		25,000	$	0.0010	$	-
Preferred Series B		50,000		600	$	0.0001	$	100		50,000		600	$	0.0001	$	100
Preferred Series C		8,000		738	$	0.0001	$	1,000		8,000		738	$	0.0001	$	1,000
Preferred Series D		20,000		305	$	0.0001	$	1,000		20,000		305	$	0.0001	$	1,000
Undesignated		3,922,000		-		-		-		3,922,000		-		-		-

On February 22, 2013, the Board of Directors of the Company authorized an amendment to the Company’s Articles of Incorporation, as amended (the “Articles of Incorporation”), in the form of a Certificate of Designation that authorized the issuance of up to one million (1,000,000) shares of a new series of preferred stock, par value $0.001 per share, designated “Series AA Super Voting Preferred Stock,” for which the board of directors established the rights, preferences and limitations thereof.

Each holder of outstanding shares of Series AA Super Voting Preferred Stock shall be entitled to one hundred thousand (100,000) votes for each share of Series AA Super Voting Preferred Stock held on the record date for the determination of stockholders entitled to vote at each meeting of stockholders of the ~~Company.~~Company. The Series AA Super Voting Preferred Stockholders will receive no dividends nor any value on liquidation. There was no activity during the three months ended March 31, 2022. As of ~~June 30, 2021,~~March 31, 2022, there were 25,000 shares of Series AA Preferred stock outstanding.

On February 7, 2017, the Company filed a certificate of designation for 50,000shares of Series B Convertible Preferred Stock designated as Series B (“Series B”) which are authorized and convertible, at the option of the holder, commencing six months from the date of issuance into common shares and warrants. For each share of Series B, the holder, on conversion, shall receive the stated value divided by 75% of the market price on the date of purchase of Series B and a ~~three~~three-year~~-year~~ warrant exercisable into up to a like amount of common shares with an exercise price of 150% of the market price as defined in the Certificate of Designation. Dividends shall be paid only if dividends on the Company’s issued and outstanding Common Stock are paid, and the amount paid to the Series B holder will be as though the conversion shares had been issued. The Series B holders have no voting rights. Upon liquidation, the holder of Series B, shall be entitled to receive an amount equal to the stated value, $100 per share, plus any accrued and unpaid dividends thereon before any distribution is made to Series C Secured Redeemable Preferred Stock or common stockholders. There was no activity during the three months ended March 31, 2022. As of ~~June 30, 2021,~~ March 31, 2022,600 shares of Series B are outstanding.

On December 22, 2017, the Company filed a certificate of designation for 8,000 shares of Series C Secured Redeemable Preferred Stock (“Series C”). Each share of the C Preferred is entitled to receive a $20.00 quarterly dividend commencing March 31, 2018, and each quarter thereafter and is to be redeemed for the stated value, $1,000 per share, plus accrued dividends in cash (i) at the Company’s option, commencing one year from issuance and (ii) mandatorily as of December 31, 2019. Management determined that the Series C should be classified as liability per the guidance in ASC 480 Distinguishing Liabilities from Equity as of December 31, 2019. On January 29, 2020, the Company filed the amended and restated certificate of designation fort its Series C Secured Redeemable Preferred Stock. The amendment changed the rights of the Series C by (a) removing the requirement to redeem the Series C, (b) removing the obligation to pay dividends on the Series C, (c) Allowing the holders of shares of Series C to convert the stated value of their shares into common stock of the Company at 75% of the closing price of such common stock on the day prior to the conversion. The C Preferred does not have any rights to vote with the common ~~stock~~stock..

Upon liquidation, the holder of Series C, shall be entitled to receive an amount equal to the stated value, $1,000 per share, plus any accrued and unpaid dividends thereon before any distribution is made to common stockholders but after distributions are made to holders of Series B.

~~During~~There was no activity during the ~~six~~three months ended ~~June 30, 2021, and 2020, the Company converted~~March 31, 2022. As of March 31, 2022, there are 25738 ~~and~~ ~~1,041~~ shares of Series C ~~into~~ outstanding

~~2,621,488~~ ~~shares of common stock. As of June 30, 2021, there are~~ ~~738~~ ~~shares of Series C outstanding.~~Notes to Condensed Consolidated Financial Statements (continued)

On November 11, 2019, the Company filed a certificate of designation for 20,000 shares of Series D Convertible Preferred Stock designated as Series D (“Series D”), which are authorized and convertible, at the option of the holder, at any time from the date of issuance, into shares of common shares. On or prior to August 1, 2020, for each share of Series D, the holder, on conversion, shall receive a number of common shares equal to 0.01% of the Company’s issued and outstanding shares on conversion date and for conversion on or after August 2, 2020, the holder shall receive conversion shares as though the conversion date was August 1, 2020, with no further adjustments for issuances by the Company of common stock after August 1, 2020, except for stock split or reverse stock splits of the common stock. Management classified the Series D in permanent equity as of ~~June 30, 2021.~~March 31, 2022.

The Series D holders have no voting rights. Upon liquidation, the holder of Series D, shall be entitled to receive an amount equal to the stated value, $1,000 per share, plus any accrued and unpaid dividends thereon before any distribution is made to common stockholders. The Company did not issue any shares of Series D in the ~~six~~three months ended ~~June 30, 2021.~~March 31, 2022. As of ~~June 30, 2021,~~March 31, 2022, there are 305 shares of Series D outstanding.

On May 18, 2020, the Company and Cavalry Fund I LP (the “investor”) entered into an Equity Line Purchase Agreement (“ELPA”) pursuant to which the investor committed to purchase, subject to certain restrictions and conditions, up to $~~10,000,000~~ (the “Commitment”) worth of the Company’s common stock, over a period of 24 months from the effectiveness of the registration statement registering the resale of shares purchased by the investor pursuant to the ELPA.

~~The Company agreed to issue shares of its common stock (the “commitment shares”) to the investor having a market value of 5% of the commitment ($500,000~~ ~~and~~ ~~3,859,630~~ ~~shares) based on the market price of the shares at the execution of the ELPA to be delivered in three tranches of~~ ~~385,963~~ shares on: (i) the execution of the ELPA; (ii) thirty days after the effectiveness of the registration statement to be filed under the RRA (the “registration right agreement” or the “registration statement”), and (iii) 90 trading days after the effectiveness of the registration statement with the balance of the commitment shares to be issued pro-rata over the first $~~3,000,000~~ ~~of puts in accordance with a formula set forth in the ELPA.~~

~~The ELPA provides that at any time after the effective date of the registration statement and provided the closing sale price of the common shares on the OTCQB is not below $0.01, from time to time on any business day selected by the Company (the “Purchase Date”), the Company shall have the right, but not the obligation, to direct the investor to buy up to~~ ~~300,000~~ shares of the common stock (the “regular purchase amount”) at a purchase price equal to the lower of: (i) the lowest applicable sales price on the date of the put and (ii) 85% of the arithmetic average of the 3 lowest closing prices for the common stockActivity during the ~~10 consecutive trading days ending on the trading day immediately preceding such put date. The regular purchase amount may be increased as follows: to up to~~ ~~400,000~~ ~~shares of common stock if the closing price of the common shares is not below $0.25~~ ~~per share and up to~~ ~~500,000~~ ~~shares if the closing price is not below $0.40~~ ~~per share.~~

Under the ELPA the Company has the right to submit a regular purchase notice to the investor as often as every business day. The payment for the shares covered by each put notice will generally occur on the day following the put notice. The ELPA contains provisions which allow for the Company to make additional puts beyond the regular purchase amount at greater discounts to the market price of the common stock as forth in the ELPA.

~~The ELPA requires the Company to apply at least~~ ~~50%~~ ~~of the proceeds of puts to the payment of certain variable rate convertible notes issued by the Company. The Company does not anticipate that it will raise any funds under the ELPA.~~three months ended March 31, 2022

During the ~~six~~three months ended ~~June 30, 2021,~~March 31, 2022, the Company issued ~~21,490,651~~3,700,000 shares of common stock for the conversion of $74,000 of principal notes and accrued interest in the amount of $~~374,335~~88,800.

During the ~~six~~three months ended ~~June 30,~~March 31, 2022, the Company issued 2,428,777 shares of common stock pursuant to a make-whole provision from an April 2021 debt settlement with one investor.

During the three months ended March 31, 2022, the Company issued 700,000 shares of common stock labelled as commitment shares in connection with the issuance of promissory notes.

During the three months ended March 31, 2021, the Company issued ~~2,500,334~~17,686,548 shares of common stock for the conversion of notes and accrued interest in the amount of $310,046.

During the three months ended March 31, 2021, the Company issued 2,300,334 shares of common stock labeled as commitment shares in connection with the issuance of promissory notes.

During the ~~six~~three months ended ~~June 30,~~March 31, 2021, the Company issued 7,000,000 shares of common stock ~~pursuant to securities purchase agreement~~ for total consideration of $126,000.

~~During the six months ended June 30, 2021, the Company issued~~ ~~1,111,111~~ ~~shares of common stock with a value of $33,333, related to the conversion of Series C.~~

~~During the six months ended June 30, 2021, the Company issued~~ ~~4,020,986~~ ~~shares of common stock with a value of $142,424, related to the settlement of debts, of which~~ ~~2,505,834~~ ~~shares of common stock were issued with a fair value of $84,697~~ ~~to a former related party.~~

~~During the six months ended June 30, 2020, the Company issued~~ ~~7,741,335~~ ~~shares of common stock for the conversion of notes and accrued interest in the amount of $1,311,240~~.

~~During the six months ended June 30, 2020, the Company issued~~ ~~2,621,488~~ ~~shares of common stock with a value of $1,387,600, related to the conversion of Series C.~~

~~During the six months ended June 30, 2020, the Company issued~~ ~~58,428~~ ~~shares of common stock to Series C with a value of $8,152~~ ~~to convert into shares of common stock.~~

~~During the six months ended June 30, 2020, the Company issued~~ ~~25,000~~ ~~shares of common stock with a value of $3,500~~ ~~related to services.~~

~~During the six months ended June 30, 2020, the Company issued~~ ~~409,000~~ ~~shares with a value of $58,855~~ ~~to one investor to exchange one variable convertible note with remaining principal of $283,000~~ ~~past maturity for a fixed rate convertible note with principal of $525,000~~ ~~and maturing one year from issuance. The Company recorded a loss on debt extinguishment of $151,496~~ ~~for the fair value of the shares issued in accordance with guidance in ASC 470-50~~ ~~Debt-Modifications and Extinguishments~~.

The balance of all stock options outstanding as of ~~June 30, 2021,~~March 31, 2022, is as follows:

				Weighted Average		Weighted Average Remaining		Aggregate				Weighted Average		Weighted Average Remaining		Aggregate
				Exercise Price		Contractual		Intrinsic				Exercise Price		Contractual		Intrinsic
	Options			Per Share		Term (years)		Value		Options		Per Share		Term (years)		Value
Outstanding at January 1, 2021		3,014,080		$	0.37		1.67		-
Outstanding at January 1, 2022											513,730	$	1.43		0.76		-
Granted		-		$	-		-		-		-	$	-		-		-
Cancelled		(350	)	$	47.00		-		-		-	$	-		-		-
Exercised		-		$	-		-		-		-	$	-		-		-
Outstanding at June 30, 2021		3,013,730		$	0.37		2.55	$	-
Outstanding at March 31, 2022											513,730	$	1.43		0.51	$	-

Exercisable at June 30, 2021		1,013,730		$	0.80		1.58	$	-
Exercisable at March 31, 2022											513,730	$	1.43		0.51	$	-

Share-based compensation expense for the ~~six~~three months ended ~~June 30,~~March 31, 2022, and 2021, totaled $~~40,961~~0.

~~The total unrecognized compensation expense amounts to approximately $157,000~~ and ~~should be recognized evenly over a 22.8-month period.~~$20,471

~~On June 11, 2020, the Board of Directors approved the issuance of~~ ~~74,668,000~~ non-incentive stock options to officers, directors, and key consultants. The key terms and conditions of the award have not been mutually understood and agreed upon, and as a result, the Company has not recognized stock compensation for such award for the six months ended June 30, 2021., respectively.

A summary of the status of the warrants granted under these agreements at ~~June 30, 2021,~~March 31, 2022, and changes during the ~~six~~three months then ended is presented below:

One executive officer of the Company has agreed to defer a portion of his compensation until cash flow improves. As of ~~June 30, 2021,~~March 31, 2022, the balance of the deferred compensation was $~~400,789~~417,318, which reflects $~~150,000~~75,000 accrual of deferred compensation and approximately $~~86,679~~51,500 cash repayment of deferred compensation during the ~~six~~three months ended ~~June 30, 2021.~~March 31, 2022.

One former executive of the Company has agreed to defer a portion of his compensation until cash flow improves. As of ~~June 30, 2021,~~March 31, 2022, the balance of his deferred compensation was $632,257. No activity occurred during the ~~six~~three months ended ~~June 30, 2021.~~March 31, 2022

From time-to-time officer of the Company advance monies to the Company to cover costs. The balance of short-term advances due to one officer of the Company at ~~June 30, 2021,~~March 31, 2022, was $~~6,529~~125 and is included in the Company’s accounts payable balance as of ~~June 30, 2021.~~March 31, 2022. During the ~~six~~three months ended ~~June 30, 2021,~~March 31, 2022, the Company’s executive officer advanced an aggregate amount of $~~19,750~~4,062 for corporate expenses, ~~and notes repayment,~~ of which $~~19,750~~4,062 was repaid back as of ~~June 30, 2021.~~March 31, 2022.

~~At June 30, 2021,~~As of March 31, 2022, notes payable ~~remain~~remained outstanding to the former President of the Company, in the amount of $~~121,000~~123,100. ~~At June 30, 2021,~~As of March 31, 2022, accrued interests on these notes payable totaled $~~61,026~~70,980, and are included in accrued expenses on the condensed consolidated balance sheet.

The Company has issued Variable Debentures which contained variable conversion rates based on unknown future prices of the Company’s common stock. This results in a conversion feature. The Company measures the conversion feature using the Black Scholes option pricing model using the following assumptions:

		Six months ended June 30,			Three months ended March 31,
		2021		2020	2022	2021

Expected term		1 – 4 months		-	1 months	1 – 4 months
Exercise price	$	0.012-$0.028		-	$0.0098-$0.015	$0.012-$0.028
Expected volatility		182%-206	%	-	153%	182%-206%
Expected dividends		NaN		-	NaN	NaN
Risk-free interest rate		0.07% to 0.13	%	-	1.63%	0.07% to 0.13%
Forfeitures		NaN		-	NaN	NaN

The assumptions used in determining fair value represent management’s best estimates, but these estimates involve inherent uncertainties and the application of management’s judgment. As a result, if factors change, including changes in the market value of the Company’s common stock, managements’ assessment, or significant fluctuations in the volatility of the trading market for the Company’s common stock, the Company’s fair value estimates could be materially different in the future.

The Company computes the fair value of the derivative liability at each reporting period and the change in the fair value is recorded as non-cash expense or non-cash income. The key component in the value of the derivative liability is the Company’s stock price, which is subject to significant fluctuation and is not under its control. The resulting effect on net loss is therefore subject to significant fluctuation and will continue to be so until the Company’s Variable Debentures, which the convertible feature is associated with, are converted into common stock or paid in full with cash. Assuming all other fair value inputs remain constant, the Company will record non-cash expense when its stock price increases and non-cash income when its stock price decreases.

The following table presents changes in the liabilities with significant unobservable inputs (level 3) for the ~~six~~three months ended ~~June 30, 2021:~~March 31, 2022:

Accounting guidance on fair value measurements and disclosures defines fair value, establishes a framework for measuring the fair value of assets and liabilities using a hierarchy system, and defines required disclosures. It clarifies that fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the market in which the reporting entity transacts business.

The Company’s balance sheet contains derivative liabilities that are recorded at fair value on a recurring basis. The three-level valuation hierarchy for disclosure of fair value is as follows:

Level 1: uses quoted market prices in active markets for identical assets or liabilities.

Level 2: uses observable market-based inputs or unobservable inputs that are corroborated by market data.

The fair value of the Company’s recorded derivative liability is determined based on unobservable inputs that are not corroborated by market data, which require a Level 3 classification. A Black Scholes option pricing model was used to determine the fair value. The Company records derivative liability on the condensed consolidated balance sheets at fair value with changes in fair value recorded in the condensed consolidated statements of operation.

The following table presents balances in the liabilities with significant unobservable inputs (Level 3) ~~at June 30, 2021:~~as of March 31, 2022:

	(Level 1)		(Level 2)		(Level 3)		Total		Fair Value Measurements Using
	Fair Value Measurements Using								Quoted Prices in
	Quoted Prices in		Significant						Active Markets for		Significant Other		Significant
	Active Markets for		Other Observable		Significant Unobservable				Identical Assets		Observable Inputs		Unobservable Inputs
	Identical Assets		Inputs		Inputs				(Level 1)		(Level 2)		(Level 3)		Total
	(Level 1)		(Level 2)		(Level 3)		Total

As of June 30, 2021
As of March 31, 2022
Derivative liability	$	-	$	-	$	5,903,803	$	5,903,803	$	-	$	-	$	4,972,655	$	4,972,655
Total	$	-	$	-	$	5,903,803	$	5,903,803	$	-	$	-	$	4,972,655	$	4,972,655

~~The Company is a defendant~~We were defendants in a case ~~brought by~~ entitled Auctus Fund, LLC ~~seeking~~v. Endonovo Therapeutics, Inc. et.al 20-cv-11286-PBS filed in the Federal District Court in Massachusetts in July 2020. The complaint sought damages related to ~~enforce~~ a variable rate convertible note dated in August 2019 ~~which was~~ in the original amount of $275,250 and alleged various counts of State and Federal securities laws violations, breach of contract, fraud, consumer fraud and other claimed theories of damages while claiming damages in excess of $500,000, other unspecified damages and attorney fees. ~~The Company is vigorously defending the action and as~~Auctus filed an ~~answer with counterclaims. While~~amended complaint that was responded to by way of a motion to dismiss. On February 28, 2022, the ~~matter is in its early stages~~Court granted our motion to dismiss, refused to extend supplemental jurisdiction over the State law claims and ~~there are always uncertainties~~held that as a result of the dismissal, the Company’s counterclaims were moot. To date neither party has appealed the ruling. Due to the nature of our business, we may become active in litigation ~~management does not believe that the litigation will have a result significantly averse~~relating to the ~~Company.~~defense, or assertion of our patent rights or other corporate matters.

The Company ~~may become involved in various~~is subject to certain legal proceedings, which it considers routine to its business activities. As of March 31, 2022, the Company believes, after consultation with legal counsel, that the ultimate outcome of such legal proceedings, whether individually or in the ~~normal course~~aggregate, is not likely to have a material adverse effect on the Company’s financial position, results of ~~business.~~operations or liquidity.

During the ~~six~~three months ended ~~June 30, 2021,~~March 31, 2022, we had two significant customers, which accounted for approximately ~~47%~~ 72%of sales.

We also have a single source for our bioelectric medical devices, which account for 100% of our sales. The interruption of products provided by this supplier would adversely affect our business and financial condition unless an alternative source of products could be found.

At ~~June 30, 2021,~~March 31, 2022, we had ~~one customer~~two customers which accounted for approximately ~~48%~~100% of our account receivable balances.

Subsequent to ~~June 30, 2021, an~~March 31, 2022, the Company executed two convertible notes for a total aggregate of ~~2,600,000~~ ~~shares of restricted common stock were issued on the conversion~~principal of $~~44,839~~ 150,000, carrying coupon of ~~principal and $7,161~~ 15%, with due date at the earlier of ~~accrued interest pursuant~~30 days after qualification of Form 1-A or nine (9) months from issuance date, convertible six (6) months from issuance date at a fixed conversion rate. Pursuant to ~~one fixed promissory note.~~the executed share purchase agreements, the Company should issue fully vested 1,050,000 commitment shares.

Subsequent to ~~June 30, 2021, an aggregate~~March 31, 2022, the Board of director approved the issuance of ~~2,500,000~~67,500,000 shares of ~~restricted~~ common stock for past services with estimated fair value of approximately $1.3 million, of which 58,250,000 shares have been issued at this Quarterly Report release date.

The Company has evaluated all events that occurred after the balance sheet date through the date when the financial statements were issued ~~pursuant~~ to ~~consulting agreement.~~determine if they must be reported. The Management of the Company determined that there were no other reportable subsequent events to be disclosed besides those noted above.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The information contained in Item 2 contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Actual results may materially differ from those projected in the forward-looking statements as a result of certain risks and uncertainties set forth in this report. Although management believes that the assumptions made and expectations reflected in the forward-looking statements are reasonable, there is no assurance that the underlying assumptions will, in fact, prove to be correct or that actual results will not be different from expectations expressed in this report.

This filing contains a number of forward-looking statements which reflect management’s current views and expectations with respect to our business, strategies, products, future results and events, and financial performance. All statements made in this filing other than statements of historical fact, including statements addressing operating performance, events, or developments which management expects or anticipates will or may occur in the future, including statements related to distributor channels, volume growth, revenues, profitability, new products, adequacy of funds from operations, statements expressing general optimism about future operating results, and non-historical information, are forward looking statements. In particular, the words “believe,” “expect,” “intend,” “anticipate,” “estimate,” “may,” and variations of such words, and similar expressions identify forward-looking statements, but are not the exclusive means of identifying such statements, and their absence does not mean that the statement is not forward-looking. These forward-looking statements are subject to certain risks and uncertainties, including those discussed below. Our actual results, performance or achievements could differ materially from historical results as well as those expressed in, anticipated, or implied by these forward-looking statements. We do not undertake any obligation to revise these forward-looking statements to reflect any future events or circumstances.

Readers should not place undue reliance on these forward-looking statements, which are based on management’s current expectations and projections about future events, are not guarantees of future performance, are subject to risks, uncertainties and assumptions (including those described below), and apply only as of the date of this filing. Our actual results, performance or achievements could differ materially from the results expressed in, or implied by, these forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

The Company develops, manufactures and distributes evolutionary medical devices focused on the rapid healing of wounds and reduction of pain, edema and inflammation in the human body. The Company’s non-invasive bioelectric medical devices are designed to target inflammation, cardiovascular diseases, chronic kidney disease, and central nervous system disorders (“CNS” disorders).

Our independent registered auditors included an explanatory paragraph in their opinion on our consolidated financial statements as of and for the fiscal year ended December 31, ~~2020,~~2021, that states that our ongoing losses and lack of resources causes doubt about our ability to continue as a going concern.

The World Health Organization declared the Coronavirus outbreak a pandemic on March 11, 2020, and in the United States various emergency actions have been taken on the National, State and Local levels. The effects of this pandemic on the Company’s business are uncertain.

A summary of our significant accounting policies is included in Note 1 of the “Notes to the Consolidated Financial Statements,” contained in our Form 10-K for the year ended December 31, ~~2020.~~2021. Management believes that the consistent application of these policies enables us to provide users of the financial statements with useful and reliable information about our operating results and financial condition. The summary condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the U.S., which require us to make estimates and assumptions. We did not experience any significant changes during the ~~six~~three months ended ~~June 30, 2021,~~March 31, 2022, in any of our Critical Accounting Policies from those contained in our Form 10-K for the year ended December 31, ~~2020.~~2021.

See Note 1 of Notes to Condensed Consolidated Financial Statements for further discussion of new accounting standards that have been adopted or are being evaluated for future adoption.

~~Six~~Three Months ended ~~June 30, 2021,~~March 31, 2022, and ~~2020.~~2021.

	Six Months Ended June 30,						Favorable						Three Months Ended March 31,						Favorable
	2021			2020			(Unfavorable)			%			2022			2021			(Unfavorable)			%

Revenue	$	64,999		$	114,316		$	(49,317	)		-43.1	%	$	2,282		$	34,715		$	(32,433	)		-93.4	%
Cost of revenue		3,021			17,560			14,539			82.8	%		714			2,521			1,807			71.7	%
Gross profit		61,978			96,756			(34,778	)		-35.9	%		1,568			32,194			(30,626	)		-95.1	%

Operating expenses		1,222,475			1,378,194			155,719			11.3	%		487,330			622,638			135,308			21.7	%

Loss from operations		(1,160,497	)		(1,281,438	)		120,941			9.4	%		(485,762	)		(590,444	)		104,682			17.7	%

Other expense		(2,817,053	)		3,985,205			(6,802,258	)		170.6	%
Other (expense) income														(1,927,447	)		(2,090,437	)		162,990			7.8	%

Net loss	$	(3,977,550	)	$	2,703,767		$	(6,681,317	)		247.1	%	$	(2,413,209	)	$	(2,680,881	)	$	267,672			10.0	%

Revenue of the Company’s SofPulse® product during the ~~six~~three months ended ~~June 30, 2021,~~March 31, 2022, was ~~$64,999,~~$2,282, a decrease of ~~$49,317,~~$32,433, or approximately ~~43%~~93%, compared to ~~$114,316~~$34,715 for the ~~six~~three months ended ~~June 30, 2020.~~March 31, 2021.

Revenues for our SofPulse® product is typically recognized at the time the product is shipped, at which time the title passes to the customer, and there are no further performance obligations. Revenue ~~has been~~continues to be negatively impacted by the COVID-19 contagious disease outbreak in March 2020. We anticipate that revenue will increase in future periods as the roll out of the SofPulse® product continues.

Cost of revenue during the ~~six~~three months ended ~~June 30, 2021,~~March 31, 2022, was ~~$3,021,~~$714, a decrease of ~~$14,539~~$1,807 or ~~82.8%~~71.7% compared to ~~$17,560~~$2,521 for the ~~six~~three months ended ~~June 30, 2020.~~March 31, 2021. Cost of revenue is recognized on those sales recorded as gross for which we are the principal in the transaction as opposed to net sales which reflect no cost of revenue. It is anticipated that cost of revenue will increase in future quarters as the roll out of the SofPulse® product continues.

Operating expenses decreased by ~~$155,719~~$135,308 or ~~11.3%~~21.7%, to ~~$1,222,475~~$487,30 for the ~~six~~three months ended ~~June 30, 2021,~~March 31, 2022, compared to ~~$1,378,194~~$622,638 for the ~~six~~three months ended ~~June 30, 2020.~~March 31, 2021. This change was due primarily to a decrease in consulting fees of approximately ~~$35k,~~$75,000 a decrease in ~~payroll fee~~stock-based compensation by approximately ~~$88k and commission expenses~~$20,000, a decrease in professional fees by approximately ~~$33k, offset by increase of $57k in regulatory fees.~~$19,000.

Other expense for the ~~six~~three months ended ~~June 30, 2021,~~March 31, 2022, was ~~$2,817,053~~$1,927,447 compared to an ~~income~~expense of ~~$3,985,205~~$2,090,437 for the ~~six~~three months ended ~~June 30, 2020.~~March 31, 2021. This change was due primarily to a change in valuation of our derivative liabilities of approximately ~~$8.0 million offset by a decrease of approximately $0.6 million in interest expense and a decrease of approximately $0.6 million in loss from debt extinguishment.~~$170,000. We anticipate ~~continued~~ large fluctuations in other income/expense ~~as a result of~~following quarterly re-evaluation of derivative liabilities.

Revenue of the Company’s SofPulse® product during the three months ended June 30, 2021, was $30,284, a decrease of $14,347, or 32.1%, compared to $44,631 for the six months ended June 30, 2020. Revenues for our SofPulse® product is typically recognized at the time the product is shipped, at which time the title passes to the customer, and there are no further performance obligations. Revenue has been negatively impacted by the COVID-19 contagious disease outbreak in March 2020. We anticipate that revenue will continue to increase in future periods as the roll out of the SofPulse® product continues.

Cost of revenue during the three months ended June 30, 2021, was $500, a decrease of $10,800 or 95.6% compared to $11,300 for the three months ended June 30, 2020. Cost of revenue is recognized on those sales recorded as gross for which we are the principal in the transaction as opposed to net sales which reflect no cost of revenue. It is anticipated that cost of revenue will increase in future quarters as the roll out of the SofPulse® product continues.

Operating expenses decreased by $35,320 or 5.6%, to $599,837 for the three months ended June 30, 2021, compared to $635,157 for the three months ended June 30, 2020. This change was due primarily to a decrease in professional fees of approximately $34,000, decrease in stock-based compensation of approximately $35,000, offset by an increase in regulatory fees of approximately $24,000 and an increase in consulting fees of approximately $34,000.

Other expense for the three months ended June 30, 2021, was $726,616 compared to $1,032,825 for the three months ended June 30, 2020. This change was due primarily to a change in valuation of our derivative liabilities of approximately $141,000 coupled with a decrease in interest expense of approximately $144,000. We anticipate continued large fluctuations in other income (expense) as a result of quarterly re-evaluation of derivative liabilities.

	As of									As of
	June 30, 2021			December 31, 2020			Favorable (Unfavorable)			March 31, 2022			December 31, 2021			Favorable (Unfavorable)
Working Capital

Current assets	$	38,680		$	46,187		$	(7,507	)	$	64,427		$	94,855		$	(30,428	)
Current liabilities		19,178,690			16,825,821			(2,352,869	)		19,772,066			17,701,710			(2,070,356	)
Working capital deficit	$	(19,140,010	)	$	(16,779,634	)	$	(2,360,376	)	$	(19,707,639	)	$	(17,606,855	)	$	(2,100,784	)

Long-term debt	$	79,825		$	155,000		$	75,175		$	79,825		$	79,825		$	-

Stockholders’ deficit	$	(16,984,023	)	$	(14,373,786	)	$	(2,610,237	)	$	(18,036,836	)	$	(15,774,324	)	$	(2,262,512	)

	Six Months Ended June 30,						Favorable			Three Months Ended March 31,						Favorable
	2021			2020			(Unfavorable)			2022			2021			(Unfavorable)
Statements of Cash Flows Select Information

Net cash provided (used) by:
Operating activities	$	(425,882	)	$	(297,215	)	$	(128,667	)	$	(122,954	)	$	(289,948	)	$	166,994
Investing activities	$	-		$	-		$	-		$	-		$	-		$	-
Financing activities	$	421,000		$	278,500		$	142,500		$	97,000		$	362,500		$	(265,500	)

	As of							As of				Favorable
	June 30, 2021		December 31, 2020		Favorable (Unfavorable)			March 31, 2022		December 31, 2021		(Unfavorable)
Balance Sheet Select Information

Cash	$	8,538	$	13,420	$	(4,882	)	$	59,982	$	85,936	$	(25,954	)

Accounts payable and accrued expenses	$	6,615,547	$	5,989,185	$	(626,362	)	$	7,506,358	$	7,078,283	$	(428,075	)

Since January 1, ~~2021,~~2022, and through ~~June 30, 2021,~~March 31, 2022, the Company has raised approximately ~~$0.5~~$0.1 million in ~~equity and~~ debt transactions. These funds have been used to ~~commence the operations of the Company to acquire and begin the development of its intellectual property portfolio. These activities include attending trade shows and~~fund on-going corporate ~~development.~~operations. Our accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for the twelve-month period following the date of these condensed consolidated financial statements. Our cash on hand at March 31, 2022 was less than $60,000. The Company has incurred substantial losses since inception. Its current liabilities exceed its current assets and available cash is not sufficient to fund expected future operations. The Company is contemplating raising additional capital through debt and equity ~~securities~~ in order to continue the funding of its ~~operations.~~operations and to acquire a profitable business. However, there is no assurance that the Company can raise ~~enough~~sufficient funds or generate sufficient revenues to pay its obligations as they become due, which raises substantial doubt about our ability to continue as a going concern. To reduce the risk of not being able to continue as a going concern, management is commercializing its FDA cleared and CE marked products and has commenced its business plan to materialize revenues from potential, future, license agreements, has raised capital through the sale of its common stock and is seeking out profitable companies. Our cash on hand at June 30, 2021 was less than $10,000. This will be insufficient to fund operations if additional capital is not raised. The Company raised an aggregate of $ 451,000 through the sale of equity and debt securities during the six months ended June 30, 2021.

The Company is not aware of any recently issued accounting pronouncements that when adopted will have a material effect on the Company’s financial position or result of its operation.

We are a Smaller Reporting Company and are not required to provide the information under this item.

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports, filed under the Securities Exchange Act of 1934, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable and not absolute assurance of achieving the desired control objectives. In reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. In addition, the design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, a control may become inadequate because of changes in conditions or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

As required by the SEC Rule 13a-15(b), we carried out an evaluation under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. Based on the foregoing, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were not effective at the reasonable assurance level due to the material weaknesses described below.

In light of the material weaknesses described below, we performed additional analysis and other post-closing procedures to ensure our financial statements were prepared in accordance with generally accepted accounting principles. Accordingly, we believe that the financial statements included in this report fairly present, in all material respects, our financial condition, results of operations and cash flows for the periods presented.

A material weakness is a control deficiency (within the meaning of the Public Company Accounting Oversight Board (PCAOB) Auditing Standard No. 2) or combination of control deficiencies that result in more than a remote likelihood that a material misstatement of the annual or interim financial statements will not be prevented or detected. Management has identified the following two material weaknesses which have caused management to conclude that as of ~~June 30, 2021,~~March 31, 2022, our disclosure controls and procedures were not effective at the reasonable assurance level:

1. We do not have written documentation of our internal control policies and procedures. Written documentation of key internal controls over financial reporting is a requirement of Section 404 of the Sarbanes-Oxley Act which is applicable to us for the quarter ended ~~June 30, 2021.~~March 31, 2022. Management evaluated the impact of our failure to have written documentation of our internal controls and procedures on our assessment of our disclosure controls and procedures and has concluded that the control deficiency that resulted represented a material weakness.

2. We do not have sufficient segregation of duties within accounting functions, which is a basic internal control. Due to our size and nature, segregation of all conflicting duties may not always be possible and may not be economically feasible. However, to the extent possible, the authorization of transactions, the custody of assets and the recording of transactions should be performed by separate individuals. The recording of transactions function is maintained by a third-party consulting firm whereas authorization and custody remains under the Company’s Chief Executive Officer’s responsibility. Management evaluated the impact of our failure to have segregation of duties on our assessment of our disclosure controls and procedures and has concluded that the control deficiency that resulted represented a material weakness.

To address these material weaknesses, management performed additional analyses and other procedures to ensure that the financial statements included herein fairly present, in all material respects, our financial position, results of operations and cash flows for the periods presented.

There has been no change in our internal control over financial reporting that occurred during the fiscal quarter covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

We ~~are~~were defendants in a case entitled Auctus Fund, LLC v. Endonovo Therapeutics, Inc. et.al 20-cv-11286-PBS filed in the Federal District Court in Massachusetts in July 2020. The complaint sought damages related to a variable rate convertible note dated in August 2019 in the original amount of $275,250 and alleged various counts of State and Federal securities laws violations, breach of contract, fraud, consumer fraud and other claimed theories of damages while claiming damages in excess of $500,000, other unspecified damages and attorney fees. Auctus filed an amended complaint that was responded to by way of a motion to dismiss. On February 28, 2022, the Court granted our motion to dismiss, refused to extend supplemental jurisdiction over the State law claims and held that as a result of the dismissal, the Company’s counterclaims were moot. To date neither party has appealed the ruling. Due to the nature of our business, we may become active in litigation relating to the defense, or assertion of our patent rights or other corporate matters.

The Company is subject to certain legal proceedings, which it considers routine to its business activities. As of March 31, 2022, the Company believes, after consultation with legal counsel, that the ultimate outcome of such legal proceedings, whether individually or in the aggregate, is not ~~currently involved in any litigation that we believe could~~likely to have a material adverse effect on ~~our~~the Company’s financial ~~condition or~~position, results of ~~operations. There is no action, suit, proceeding, inquiry~~operations or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the executive officers of our company or any of our subsidiaries, threatened against or affecting our company, our common stock, any of our subsidiaries or of our companies or our subsidiaries’ officers or directors in their capacities as such, in which an adverse decision could have a material adverse effect.liquidity.

We are a Smaller Reporting Company (as defined in Rule 12b-2 of the Exchange Act) and are not required to provide the information under this item.

Number of	Number of
Common Shares	Common Shares	Source of			Source of
Issued	Issued	Payment	Amount		Payment	Amount

	21,490,651	Conversion of notes	$	949,743
	1,111,111	Conversion of Preferred Series C		33,333
	7,000,000	Issuance for cash		126,000
	4,020,986	Settlement of debt		142,424
	2,500,334	Commitment shares		108,182
3,700,000					Conversion of notes	$	88,800
2,428,777					Settlement of debt		46,147
700,000					Commitment shares		15,750

The above issuances of securities during the ~~six~~three months ended ~~June 30, 2021,~~March 31, 2022, were exempt from registration pursuant to Section 4(2), and/or Regulation D promulgated under the Securities Act. These securities qualified for exemption under Section 4(2) of the Securities Act since the issuance securities by us did not involve a public offering. The offering was not a “public offering” as defined in Section 4(2) due to the insubstantial number of persons involved in the deal, size of the offering, manner of the offering and number of securities offered. We did not undertake an offering in which we sold a high number of securities to a high number of investors. In addition, these stockholders had the necessary investment intent as required by Section 4(2) since they agreed to and received share certificates bearing a legend stating that such securities are restricted pursuant to Rule 144 of the Securities Act. This restriction ensures that these securities would not be immediately redistributed into the market and therefore not be part of a “public offering.” Based on an analysis of the above factors, we have met the requirements to qualify for exemption under Section 4(2) of the Securities Act for this transaction.

~~In accordance with SEC Release 33-8238, Exhibit 32.1 and 32.2 are being furnished and not filed.~~

* Furnished herewith. XBRL (Extensible Business Reporting Language) information is furnished and not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Delaware		45-2552528
(State or other jurisdiction of		(I.R.S. Employer
incorporation or organization)		Identification No.)

Large accelerated filer ☐	Accelerated filer ☐

Non-accelerated filer ☒☒	Smaller reporting company ☒

	Emerging growth company ☐

		Page Number
PART I - FINANCIAL INFORMATION

Item 1.	Condensed Consolidated Financial Statements (unaudited).	3
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations.	2120
Item 3.	Quantitative and Qualitative Disclosures About Market Risk.	2625
Item 4.	Controls and Procedures.	2625

PART II - OTHER INFORMATION

Item 1.	Legal Proceedings.	2726
Item 1A.	Risk Factors.	2726
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds.	2726
Item 3.	Defaults Upon Senior Securities.	2827
Item 4.	Mine Safety Disclosures	2827
Item 5.	Other ~~Information~~Information..	2827
Item 6.	Exhibits.	2827

SIGNATURES		2928

	Shares		Amount			Shares		Amount		Shares			Amount		Shares		Amount		Shares		Amount		Capital			Receivable			Earnings			Deficit
	Series AA Preferred Stock					Series B Convertible Preferred Stock				Series C Convertible Preferred Stock					Series D Convertible Preferred Stock				Common Stock				Additional Paid-in			Subscription			Retained			Total Shareholder’s
	Shares		Amount		��	Shares		Amount		Shares			Amount		Shares		Amount		Shares		Amount		Capital			Receivable			Earnings			Deficit
Balance December 31, 2019		25,000	$	25			600	$	1		-		$	-		255	$	-		1,189,204	$	118	$	32,432,392		$	(1,570	)	$	(52,934,786	)	$	(20,503,820	)

Reclassification Preferred Series C		-		-			-		-		1,814			-		-		-		-		-		2,418,269			-			-			2,418,269
Shares issued for Preferred Series D		-		-			-		-		-			-		50		-		-		-		50,000			-			-			50,000
Shares issued for conversion of notes payable and accrued interest		-		-			-		-		-			-		-		-		4,388,291		439		2,545,275			-			-			2,545,714
Restricted shares issued as inducement to Series C
Restricted shares issued as inducement to Series C, shares
Shares issued for conversion of Preferred Series C to common share		-		-			-		-		(990	)		-		-		-		1,636,166		164		(164	)		-			-			-
Common stock issued for services
Common stock issued for services, shares
Commitment shares
Commitment shares, shares
Shares issued as settlement of debt with former related party
Shares issued as settlement of debt with former related party, shares
Common stock issued with exchange of convertible notes
Common stock issued with exchange of convertible notes, shares
Common Shares issued for debt
Common Shares issued for debt, shares
Valuation of stock options issued for services		-		-			-		-		-			-		-		-		-		-		9,567			-			-			9,567
Shares issued as commitment to note holders
Shares issued as commitment to note holders, Shares
Common stock issued for cash
Common stock issued for cash, shares
Shares issued as commitment to note holders, Shares
Net loss for the quarter ended March 31, 2020		-		-			-		-		-			-		-		-		-		-					-			4,338,418			4,338,418
Balance March 31, 2020		25,000	$	25			600	$	1		824		$	-		305	$	-		7,213,661	$	721	$	37,455,339		$	(1,570	)	$	(48,596,368	)	$	(11,141,852	)

Shares issued for conversion of Preferred Series C to Common share		-		-			-		-		(105	)		-		-		-		985,322		99		27			-			-			126
Shares issued for conversion of notes payable and accrued interest		-		-			-		-		-			-		-		-		3,353,044		335		475,627			-			-			475,962
Restricted shares issued as inducement to Series C		-		-			-		-		-			-		-		-		58,428		6		8,146			-			(8,152	)		-
Common stock issued for services		-		-			-		-		-			-		-		-		25,000		3		3,497			-			-			3,500
Commitment shares		-		-			-		-		-			-		-		-		385,963		39		55,501			-			-			55,540
Common stock issued with exchange of convertible notes		-		-			-		-		-			-		-		-		409,000		41		58,814			-			-			58,855
Net loss for the quarter ended June 30, 2020		-		-			-		-		-			-		-		-		-		-		-			-			(1,634,651	)		(1,634,651	)
Balance June 30, 2020		25,000	$	25			600	$	1		719		$	-		305	$	-		12,430,418	$	1,244	$	38,056,951		$	(1,570	)	$	50,239,171	)	$	(12,182,520	)

	2021			2020
	Six months ended June 30,
	2021			2020
Numerator:
Net income (loss) attributable to common shareholders	$	(3,997,550	)	$	2,703,767

Effect of dilutive securities
Convertible notes		-			(4,921,950	)
Net loss for diluted earnings per share	$	(3,997,550	)	$	(2,218,183	)
Denominator:
Weighted-average number of common shares outstanding during the period		50,084,150			6,368,543
Dilutive effect of convertible notes payable		-			8,696,619
Common stock and common stock equivalents used for diluted earnings per share		50,084,150			15,065,162


	Series AA			Series B Convertible			Series D Convertible			Series C Convertible						Additional								Total
	Preferred Stock			Preferred Stock			Preferred Stock			Preferred Stock			Common Stock			Paid-in		Subscription			Retained			Shareholder’s
	Shares	Amount		Shares	Amount		Shares	Amount		Shares	Amount		Shares	Amount		Capital		Receivable			Earnings			Deficit

Balance December 31, 2021	25,000	$	25	600	$	1	305	$	-	738		-	74,498,761	$	7,449	$	40,663,187	$	(1,570	)	$	(56,443,416	)	$	(15,774,324	)

Shares issued for conversion of notes payable and accrued interest	-		-	-		-	-		-	-		-	3,700,000		370		88,430		-			-			88,800
Shares issued for settlement of debt	-		-	-		-	-		-	-		-	2,428,777		243		45,904		-			-			46,147
Issuance of commitment shares in connection with promissory note	-		-	-		-	-		-	-		-	700,000		70		15,680		-			-			15,750
Net loss for the quarter ended March 31, 2022	-		-	-		-	-		-	-		-	-		-		-		-			(2,413,209	)		(2,413,209	)
Balance March 31, 2022	25,000	$	25	600	$	1	305	$	-	738	$	-	81,327,538	$	8,132	$	40,813,201	$	(1,570	)	$	(58,856,625	)	$	(18,036,836	)

	June 30, 2021		December 31, 2020

Autos	$	64,458	$	64,458
Medical equipment		13,969		13,969
Other equipment		11,367		11,367
Property, Plant and Equipment, gross		89,794		89,794
Less accumulated depreciation		89,794		88,214
Property, Plant and Equipment, net	$	-	$	1,580


Twelve Months Ending June 30,	Amount

2021	$	646,910
2022		646,910
2023		646,910
2024		295,082

Total	$	2,235,812

Twelve Months Ending March 31,	Amount

2022	$	646,910
2023		646,910
2024		456,808

Total	$	1,750,628

	June 30, 2021			December 31, 2020

Notes payable at beginning of period	$	6,835,196		$	6,874,795
Notes payable issued		325,000			1,364,611
Liquidated damages		-			452,095
Note modification		-			25,190
Loan fees added to note payable		-			120,389
Repayments of notes payable in cash		(30,000	)		(22,000	)
Settlements on note payable		(117,770	)		(697,253	)
Less amounts converted to stock		(282,850	)		(1,282,631	)
Notes payable at end of period		6,729,576			6,835,196
Less debt discount		(70,236	)		(201,157	)
Note payable, net	$	6,659,340		$	6,634,039

Notes payable issued to a former related party	$	121,000		$	143,000
Notes payable issued to non-related parties	$	6,538,340		$	6,491,039

	Notes to
12 months ending,	Former Related party		Non-related parties		Total

Past due	$	121,000	$	3,446,126	$	3,567,126
June 30, 2022		-		3,162,450		3,162,450
	$	121,000	$	6,608,576	$	6,729,576

	Outstanding Warrants
				Weighted Average		Weighted Average Remaining
				Exercise Price		Contractual
	Shares			Per Share		Term (years)
Outstanding at January 1, 2022		22,200		$	59.25		0.32
Granted		-		$	-		-
Cancelled		(12,430	)	$	41.06		-
Exercised		-		$	-
Outstanding at March 31, 2022		9,770		$	82.40		0.28

Exercisable at March 31, 2022		9,770		$	82.40		0.28

	Outstanding Warrants					Weighted
				Weighted Average		Average Remaining
				Exercise Price		Contractual
	Shares			Per Share		Term (years)
Outstanding at January 1, 2021		39,295		$	200.72		0.93
Granted		-		$	-		-
Cancelled		(10,986	)	$	489.75		-
Exercised		-		$	-
Outstanding at June 30, 2021		28,309		$	88.56		0.63

Exercisable at June 30, 2021		28,309		$	88.56		0.63

	Derivative
	Liability
Balance December 31, 2020	$	4,202,597

Extinguishment		(133,386	)
Settlements by debt settlement		(585,857	)
Change in estimated fair value		2,420,449

Balance June 30, 2021	$	5,903,803

	Three Months Ended June 30,						Favorable
	2021			2020			(Unfavorable)		%

Revenue	$	30,284		$	44,631		$	(14,347)		-32.1	%
Cost of revenue		500			11,300			10,800		95.6	%
Gross profit		29,784			33,331			(3,547)		-10.6	%

Operating expenses		599,837			635,157			35,320		5.6	%

Loss from operations		(570,053	)		(601,826	)		31,773		5.3	%

Other income (expense)		(726,616)			(1,032,825)			306,209		29.6	%

Net income (loss)	$	(1,296,669)		$	(1,634,651)		$	337,982		20.7	%

Exhibit Number		Exhibit Title

~~31.1~~31.1*		Certification of Principal Executive Officer and Principal Financial Officer, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

~~32.1~~32.1**		Certification of Principal Executive Officer and Principal Financial Officer, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS *101		The following materials from the Company’s Quarterly report for the period ended March 31, 2022, formatted in Extensible Business Reporting Language (XBRL).

101.INS		Inline XBRL Instance Document

101.SCH *		Inline XBRL Taxonomy Extension Schema Document

101.CAL *		Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF *		Inline XBRL Taxonomy Extension Definition Linkbase Document

101.LAB *		Inline XBRL Taxonomy Extension Label Linkbase Document

101.PRE *		Inline XBRL Taxonomy Extension Presentation Linkbase Document

104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

Dated: ~~August 23, 2021~~May 19, 2022	Endonovo Therapeutics, Inc.

	By:	/s/ Alan Collier
		Alan Collier
		Chief Executive Officer (Duly Authorized Officer, Principal Executive Officer, and Principal Financial Officer)